Clinical Scorecard: FDA Approves Auvelity for Agitation in Alzheimer’s Disease
At a Glance
| Category | Detail |
|---|---|
| Condition | Agitation associated with dementia due to Alzheimer’s disease |
| Key Mechanisms | Dextromethorphan acts on N-methyl-D-aspartate and sigma-1 receptors; bupropion inhibits CYP2D6. |
| Target Population | Patients with Alzheimer’s disease experiencing agitation. |
| Care Setting | Outpatient and inpatient settings for dementia care. |
Key Highlights
- Agitation affects up to 76% of Alzheimer’s patients.
- Auvelity showed significant improvement in agitation symptoms in clinical trials.
- Long-term treatment reduces relapse of agitation symptoms.
- Dosing regimen differs from major depressive disorder.
- Boxed warning for suicidal thoughts and behaviors.
Guideline-Based Recommendations
Diagnosis
- Assess agitation symptoms in patients with Alzheimer’s disease.
Management
- Initiate treatment with 30 mg/105 mg once daily, increase to twice daily after 7 days.
Monitoring & Follow-up
- Monitor for adverse reactions such as dizziness and dyspepsia.
Risks
- Monitor for seizures, increased blood pressure, and risk of serotonin syndrome.
Patient & Prescribing Data
Adults with Alzheimer’s disease experiencing agitation.
Concomitant use of monoamine oxidase inhibitors is contraindicated.
Clinical Best Practices
- Consult full prescribing information for drug interactions and contraindications.
- Do not use as an as-needed treatment for agitation.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
